Please try another search
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson’s disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 research programs for the treatment of neurodegenerative disorders and ageing; IRL1117, a drug candidate developed for once-daily oral treatment for the hallmark symptoms of Parkinson’s; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson’s disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Christer Nordstedt | 61 | 2023 | Director |
Carola Lemne | 65 | 2018 | Independent Chairman of the Board |
Catharina Gustafsson Wallich | 60 | 2022 | Independent Director |
Daniel Johnsson | 56 | 2023 | Director |
Rein Piir | 66 | 2016 | Independent Director |
Gunnar Olsson | 71 | 2017 | Director |
Veronica Wallin | 38 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review